文献速递神经肿瘤小儿神经外科与脑积水

mTOR抑制剂对结节性硬化症相关室管膜下巨细胞星形细胞瘤患者梗阻性脑积水的影响

The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
PubMed 文献 · J Neurooncol · 2020-04-13

该回顾性病例系列纳入2007年10月至2018年12月接受mTOR抑制剂治疗的13例结节性硬化症相关室管膜下巨细胞星形细胞瘤患者,评估药物对梗阻性脑积水的影响。6例脑积水改善,7例无变化,无患者脑积水加重或需分流手术;多数患者诊断时为无症状性脑积水。

要点

  • 13例接受mTOR抑制剂治疗的患者中,8例起始治疗时存在梗阻性脑积水,其中5例无症状。
  • 6例脑积水改善,7例无变化,无患者脑积水加重或需分流手术。
  • 5例有颅内压增高症状的患者中4例避免了手术。

核心结论

  • 多数患者诊断时为无症状性脑积水,脑室扩大与颅内压增高症状不相关。
  • mTOR抑制剂成功治疗结节性硬化症相关室管膜下巨细胞星形细胞瘤所致的梗阻性脑积水,即使存在急性颅内压增高症状。

研究设计与样本

  • 回顾性病例系列,纳入16例 identified 患者中的13例,2007年10月至2018年12月接受mTOR抑制剂治疗的结节性硬化症相关室管膜下巨细胞星形细胞瘤患者。
  • 系列磁共振成像和临床病历回顾,将颅内压增高症状和体征与MRI上的脑室扩大相关联。
  • 采用提出的脑室扩大分级:无(<7 mm)、轻度(7-10 mm)、中度(11-30 mm)、重度(>30 mm);梗阻性脑积水定义为基于最大测量的中度或重度脑室扩大。

主要发现

  • 患者开始mTOR抑制剂治疗的中位年龄为13(6-17)岁,5例(38%)为女性。
  • 8例患者在mTOR抑制剂起始时存在梗阻性脑积水,其中5例无症状。
  • 6例患者在mTOR抑制剂治疗后的系列MRI上脑积水改善,7例根据所用脑室扩大分级无变化。
  • 所有3例出现颅内压增高症状并伴有梗阻性脑积水的患者均存在视乳头水肿。
  • 无患者脑积水加重或需要分流置入;5例有颅内压增高症状的患者中4例避免了手术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mammalian target of rapamycin inhibitors (mTORi) are known to effectively reduce the size of subependymal giant cell astrocytomas (SEGAs), which are benign brain lesions associated with Tuberous Sclerosis Complex (TSC) that commonly cause obstructive hydrocephalus (OH). This retrospective case series reviews an institutional experience of the effect of mTORi on OH in patients with TSC-related SEGA. METHODS: Thirteen of 16 identified patients with TSC-related SEGA treated with mTORi from October 2007 to December 2018 were included. Serial magnetic resonance imaging (MRI) and clinical charts were reviewed to correlate symptoms and signs of increased intracranial pressure (iICP) with ventriculomegaly on MRI. A proposed ventriculomegaly scale was used: none (< 7 mm), mild (7-10 mm), moderate (11-30 mm), and severe (> 30 mm). OH was defined as moderate or severe ventriculomegaly, based on the largest measurement. RESULTS: Patients' median age at start of mTORi was 13 (6-17) years and five (38%) patients were female. Eight patients had OH at the time of mTORi initiation, five of whom were asymptomatic. Six patients had improvement of hydrocephalus on serial MRI imaging with mTORi therapy, while seven patients had no change based on the ventriculomegaly scale used. All three patients who presented with symptoms of iICP and had OH also had papilledema. None had worsening of hydrocephalus or required shunt placement. Out of five patients with symptoms of iICP, four avoided surgery. CONCLUSION: Most patients had asymptomatic OH at the time of diagnosis, and ventricular enlargement was not correlated with iICP symptoms. mTORi was successful for treatment of OH from TSC-related SEGA, even in the setting of acute symptoms of iICP.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Weidman DR, Palasamudram S, Zak M, et al. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). J Neurooncol. 2020. PMID: 32285309. doi:10.1007/s11060-020-03487-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。